Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensory Evaluation of Dexlansoprazole OD Tablets
NCT02096458Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexlansoprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE), sponsored by Takeda. Primary endpoint: Time to In-Vivo Disintegration of Dexlansoprazole 30 mg Orally Disintegrating Tablets at Day 1. Started Feb 2014; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT02096458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096458.